AUPH Q4 2020 Earnings — Aurinia Pharmaceuticals Inc. Revenue & Financial Results | Market Cap Arena

AUPHAurinia Pharmaceuticals Inc.

$2B

Q4 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$50M+172417.2% YoY

Gross Profit

$50M100.0% margin

Operating Income

-$8M-16.1% margin

Net Income

-$8M-16.1% margin

EPS (Diluted)

$-0.06

QoQ Revenue Growth

+172417.2%

Cash Flow

Operating Cash Flow

$5M

Free Cash Flow

$988,000

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$464M

Total Liabilities

$56M

Stockholders' Equity

$408M

Cash & Equivalents

$272M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$50M	$29,000	+172417.2%
Gross Profit	$50M	-$13M	+477.2%
Operating Income	-$8M	-$21M	+61.5%
Net Income	-$8M	-$76M	+89.4%